###begin article-title 0
###xml 96 100 <span type="species:ncbi:10090">mice</span>
TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice
###end article-title 0
###begin p 1
###xml 37 66 37 66 <email xmlns:xlink="http://www.w3.org/1999/xlink">carsten.kirschning@lrz.tum.de</email>
CORRESPONDENCE Carsten J. Kirschning:carsten.kirschning@lrz.tum.de
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 457 476 457 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica</italic>
###xml 480 496 480 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 457 476 <span type="species:ncbi:28901">Salmonella enterica</span>
###xml 480 496 <span type="species:ncbi:562">Escherichia coli</span>
###xml 884 888 <span type="species:ncbi:10090">mice</span>
###xml 954 959 <span type="species:ncbi:9606">human</span>
###xml 1059 1065 <span type="species:ncbi:10090">murine</span>
###xml 1082 1087 <span type="species:ncbi:9606">human</span>
Gram-negative bacterial infection is a major cause of sepsis and septic shock. An important inducer of inflammation underlying both syndromes is the cellular recognition of bacterial products through pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). We identified a novel antagonistic mAb (named 1A6) that recognizes the extracellular portion of the TLR4-MD-2 complex. If applied to mice before infection with clinical isolates of Salmonella enterica or Escherichia coli and subsequent antibiotic therapy, 1A6 prevented otherwise fatal shock, whereas application of 1A6 after infection was ineffective. In contrast, coapplication of 1A6 and an anti-TLR2 mAb up to 4 h after infection with Gram-negative bacteria, in combination with the start of antibiotic therapy (mimicking clinical conditions), provided robust protection. Consistent with our findings in mice, dual blockade of TLR2 and TLR4 inhibited TNF-alpha release from human peripheral blood mononuclear cells upon Gram-negative bacterial infection/antibiotic therapy. Both murine splenocytes and human PBMCs released IFN-gamma in a TLR4-dependent manner, leading to enhanced surface TLR2 expression and sensitivity for TLR2 ligands. Our results implicate TLR2 as an important, TLR4-driven sensor of Gram-negative bacterial infection and provide a rationale for blockade of both TLRs, in addition to antibiotic therapy for the treatment of Gram-negative bacterial infection.
###end p 3
###begin p 4
S. Spiller and G. Elson contributed equally to this paper.
###end p 4
###begin p 5
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 696 697 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
Sepsis is a life-threatening condition that demands treatment within few hours upon clinical manifestation (1, 2). Gram-negative and -positive bacterial infections are the major causes of sepsis, which is characterized by extension of local infection to the systemic level (3-5). Typical early findings include high serum concentrations of cytokines such as TNF-alpha. The early phase of sepsis is followed by endocrine and cardiovascular dysregulation, often triggering fatal septic shock. Evidence of a link between the initial immune hyperactivation and a later immunoparalysis contributing to sepsis mortality may emphasize a rationale for timely and transient therapeutic immunosuppression (5).
###end p 5
###begin p 6
###xml 616 617 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 619 620 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 841 842 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 844 845 840 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 982 983 978 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 985 987 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1162 1164 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1166 1168 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
Binding of pathogen-associated molecular patterns (PAMPs), such as envelope constituents or nucleic acids, to pattern recognition receptors (PRRs) induces inflammation upon infection. PRRs include Toll-like receptors (TLRs), which carry N-terminal leucine-rich repeat (LRR)-rich domains that interact with PAMPs. Ligand binding to the ectodomains induces TLR dimerization via the adjacent transmembrane domains. C-terminal intracellular domains recruit the cytoplasmic adaptor molecules MyD88 and/or TRIF/TICAM-1 to initiate intracellular signal transduction via specific pathways such as those involving NF-kappaB (6, 7). The immune-stimulatory activity of the Gram-negative bacterial outer membrane glycolipid LPS depends on binding to LPS-binding protein (LBP) and CD14. These proteins deliver LPS to the complex formed by TLR4 and MD-2 (8, 9). N-terminally oligo-acylated proteins, produced by most if not all bacteria, are PAMPs that activate TLR2-TLR1 or TLR2-TLR6 complexes (7, 10). Previous reports have shown the relative importance of TLR2 and TLR4 as sensors of Gram-negative and -positive bacteria, but have indicated involvement of additional PRRs (11, 12).
###end p 6
###begin p 7
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 158 164 <span type="species:ncbi:9986">rabbit</span>
###xml 471 477 <span type="species:ncbi:10090">murine</span>
Existing strategies for the prevention of Gram-negative bacterial septic shock target inflammatory mediators or specific PRRs such as CD14. Antagonistic anti-rabbit CD14 antibody-dependent blockade of CD14 has been shown to prevent pathology such as organ injury by repetitive LPS challenge when applied, even after the initial LPS administration (13). Efforts to inhibit LPS-induced TLR4 activation include application of LBP, antagonistic lipid A, or antagonistic anti-murine (m)TLR4 mAbs (14-16).
###end p 7
###begin p 8
###xml 84 100 84 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 104 123 104 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica</italic>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 84 100 <span type="species:ncbi:562">Escherichia coli</span>
###xml 104 123 <span type="species:ncbi:28901">Salmonella enterica</span>
###xml 195 201 <span type="species:ncbi:10090">murine</span>
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
In this study, we examined the host response to infection with clinical isolates of Escherichia coli or Salmonella enterica. Specifically, we investigated whether blockade of TLR4 and/or TLR2 on murine or human immune cells inhibits cytokine release. In addition, we studied the effect of antibiotic therapy paired with such blockade during Gram-negative bacterial infection of mice to protect against the Jarisch-Herxheimer reaction, which is induced in vivo when PAMPs are released rapidly from bacteria exposed to antibiotics (17). Results of either single or dual TLR blockade before or upon acute Gram-negative bacterial infection showed a central role of both TLR4 and TLR2 in sensing of Gram-negative bacterial challenge in vivo, a TLR4-TLR2 interrelation, and the capacity to protect from shock upon subsequent or synchronous antibiotic therapy.
###end p 8
###begin title 9
RESULTS AND DISCUSSION
###end title 9
###begin p 10
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 483 486 483 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 491 494 491 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 479 494 479 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup>/TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 547 550 547 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 543 550 543 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 653 661 653 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 945 948 945 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 941 948 941 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 953 956 953 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 949 956 949 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 963 978 963 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 1013 1016 1013 1016 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1009 1016 1009 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 1021 1024 1021 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1017 1024 1017 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 1125 1126 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1128 1136 1128 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1141 1142 1141 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1144 1148 1144 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 1192 1207 1192 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, B and C</xref>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 957 961 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
###xml 1039 1043 <span type="species:ncbi:10090">mice</span>
###xml 1090 1094 <span type="species:ncbi:10090">mice</span>
###xml 1125 1136 <span type="species:ncbi:28901">S. enterica</span>
###xml 1141 1148 <span type="species:ncbi:562">E. coli</span>
Investigating the involvement of TLR2 in addition to TLR4, we applied experimental models of Gram-negative bacterial infection and subsequent antibiotic therapy both in vitro and in vivo (18). We observed TLR2/4-independent activity of primary macrophages upon high-dose infection and subsequent antibiotic therapy affirming the involvement of further PRRs (such as TLR9 binding bacterial DNA) (6) in the recognition of Gram-negative bacteria. However, at lower infection doses, TLR2-/-/TLR4-/- macrophages were barely responsive. Substantial TLR4-/- macrophage activity upon Gram-negative bacterial challenge thus implied a contributing TLR2 activity (Fig. 1 A). Next, we infected mice with clinical isolates of Gram-negative bacteria. After 1 h, infection was terminated by antibiotic therapy, which was effective as indicated not only by the sterility of blood cultures 18 h after infection (not depicted) but also by the survival of all TLR2-/-/TLR4-/- mice (Fig. 1, B and C). As opposed to resistance of TLR2-/-/TLR4-/- mice, >50% of mice lacking expression of TLR2 or TLR4 and all WT mice succumbed to fatal shock upon S. enterica and E. coli infection (followed by antibiotic therapy; Fig. 1, B and C).
###end p 10
###begin p 11
###xml 0 131 0 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Impaired responsiveness to Gram-negative bacterial infection followed by antibiotic therapy in the absence of TLR2/TLR4 expression.</bold>
###xml 180 183 169 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 176 183 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 215 218 199 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 211 218 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 248 251 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 244 251 228 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 256 259 240 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 252 259 236 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 341 342 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 344 352 315 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 366 367 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 369 373 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 563 564 530 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 567 568 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 655 656 622 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 661 672 628 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. enterica</italic>
###xml 674 677 641 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ent</italic>
###xml 689 690 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 695 702 662 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 794 797 761 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 790 797 757 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 802 805 769 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 798 805 765 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 822 823 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
###xml 341 352 <span type="species:ncbi:28901">S. enterica</span>
###xml 366 373 <span type="species:ncbi:562">E. coli</span>
###xml 629 633 <span type="species:ncbi:10090">Mice</span>
###xml 661 672 <span type="species:ncbi:28901">S. enterica</span>
###xml 695 702 <span type="species:ncbi:562">E. coli</span>
Impaired responsiveness to Gram-negative bacterial infection followed by antibiotic therapy in the absence of TLR2/TLR4 expression. (A-C) Wild-type (white bars, open diamond), TLR2-/- (light gray bars, square), TLR4-/- (dark gray bars, *), and TLR2-/-/TLR4-/- (black bars, black triangle; A) macrophages or mice (B and C) were infected with S. enterica (A and B) or E. coli (A and C) and subjected to antibiotic therapy after 1 h (A-C). (A) Cell culture supernatants were analyzed for TNF-alpha content by ELISA 16 h after challenge or infection as indicated (Pam3CSK4, tripalmitoylated hexapeptide; ND, not detected). (B and C) Mice were infected with 109 CFU S. enterica (ent.) or 5 x 109 CFU E. coli. *, P < 0.003; **, P < 0.052; P values result from comparison to results of respective TLR2-/-/TLR4-/- group analysis; n = 5 for each experimental group.
###end p 11
###begin p 12
###xml 229 246 229 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bacillus subtilis</italic>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 630 633 630 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 626 633 626 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 768 776 768 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 856 864 856 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1106 1121 1106 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, C and D</xref>
###xml 1243 1244 1243 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1246 1250 1246 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 1549 1550 1545 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1552 1560 1548 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1564 1565 1560 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1567 1571 1563 1567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 1614 1622 1610 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 229 246 <span type="species:ncbi:1423">Bacillus subtilis</span>
###xml 464 470 <span type="species:ncbi:10090">murine</span>
###xml 531 536 <span type="species:ncbi:9606">human</span>
###xml 943 949 <span type="species:ncbi:10090">murine</span>
###xml 1243 1250 <span type="species:ncbi:562">E. coli</span>
###xml 1525 1531 <span type="species:ncbi:10090">murine</span>
###xml 1549 1560 <span type="species:ncbi:28901">S. enterica</span>
###xml 1564 1571 <span type="species:ncbi:562">E. coli</span>
In the face of predominant intracellular TLR2 localization in primary immune cells, the effectiveness of anti-TLR2 mAb (T2.5) application to inhibit surface TLR2-driven fatal shock upon challenge with the Gram-positive bacterium Bacillus subtilis has been surprising (12, 19). To extend the concept of sole TLR2 blockade and to translate it to an experimental setting mimicking sepsis upon bacterial infection, we first identified a novel mAb (1A6). 1A6 bound the murine TLR4-MD-2 complex in a dose-dependent fashion, as well as a human (h)TLR4-mMD-2 complex (Fig. S1, A-C, available at ). Fluorescent staining of WT, but not TLR4-/-, macrophages using 1A6 and subsequent flow cytometry or microscopy confirmed primarily intracellular TLR4 localization (Fig. S1 D and Fig. 2 A). Co-precipitation of mTLR4 and mMD-2 from cells overexpressing both proteins (Fig. 2 B) indicated the specificity of 1A6 for an epitope formed by both chains of the murine TLR4-MD-2 complex together. Binding of 1A6 to TLR4-MD-2, but not to TLR2, resulted in TLR4 neutralization and contrasted with the inverse features of T2.5 (Fig. 2, C and D; Fig. S2 A). Furthermore, preapplication of 1A6 reduced phosphorylation of the mitogen-activated protein kinase p38 upon E. coli infection highly effectively, whereas blockade of TLR2 on RAW264.7 macrophages that constitutively express TLR2 at a high level was less effective (Fig. S2 B and not depicted). Co-application of 1A6 and T2.5, but not single mAb application, inhibited TNF-alpha release from murine macrophages upon S. enterica or E. coli infection followed by antibiotic therapy (Fig. 2 E).
###end p 12
###begin p 13
###xml 0 126 0 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">mTLR4&#8211;MD-2 specificity of 1A6 and effective TLR4 and TLR2 blockade on murine macrophages infected with Gram-negative bacteria.</bold>
###xml 949 950 940 941 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 953 954 944 945 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 70 76 <span type="species:ncbi:10090">murine</span>
###xml 390 396 <span type="species:ncbi:10090">murine</span>
mTLR4-MD-2 specificity of 1A6 and effective TLR4 and TLR2 blockade on murine macrophages infected with Gram-negative bacteria. (A) Macrophages incubated with anti-TLR4 mAb (1A6) shown by Nomarski differential interference contrast microscopy (DIC), fluorescence recording (middle), and superimposition of both recordings (right). Bar, 10 mum. (B) Lysates of HEK293 cells that overexpressed murine TLR4 and MD-2 were subjected to immunoprecipitation (IP; alpha, anti) and analyzed using flag-specific antiserum (lys., total lysates). (C and D) HEK293 cells overexpressing mTLR4-MD-2 transiently or RAW264.7 macrophages, respectively, were challenged as indicated upon preincubation with anti-TLR2 mAb (T2.5), 1A6, or isotype control (i.c.) for 30 min. HEK293 cells were lysed 16 h after challenge and assayed for NF-kappaB-driven relative (Rel.) luciferase activity (C), whereas RAW264.7 macrophage supernatants were sampled 16 h after challenge (Pam3CSK4, tripalmitoylated hexapeptide) and analyzed by ELISA (D). *, P < 0.003. (E) RAW264.7 macrophages were infected 30 min after incubation with 1A6 (*), T2.5 (square), 1A6 and T2.5 (black triangle), or isotype control (open diamond) mAb. Antibiotic therapy started 1 h after infection, and supernatants were analyzed by ELISA 6 h after infection. Results illustrated represent similar results (A, B, and E) or summarize the results (C, D) of at least three independent experiments.
###end p 13
###begin p 14
###xml 670 671 670 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 933 939 933 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 1096 1097 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1099 1103 1099 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 1179 1182 1175 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1175 1182 1171 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 1187 1190 1183 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1183 1190 1179 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 1255 1266 1251 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A&#8211;C</xref>
###xml 1292 1293 1288 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1295 1303 1291 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1468 1476 1464 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 1541 1542 1537 1538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1544 1552 1540 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1699 1707 1695 1703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 E</xref>
###xml 274 278 <span type="species:ncbi:10090">Mice</span>
###xml 896 900 <span type="species:ncbi:10090">mice</span>
###xml 905 911 <span type="species:ncbi:10090">murine</span>
###xml 1096 1103 <span type="species:ncbi:562">E. coli</span>
###xml 1191 1195 <span type="species:ncbi:10090">mice</span>
###xml 1217 1221 <span type="species:ncbi:10090">mice</span>
###xml 1249 1253 <span type="species:ncbi:10090">mice</span>
###xml 1292 1303 <span type="species:ncbi:28901">S. enterica</span>
###xml 1541 1552 <span type="species:ncbi:28901">S. enterica</span>
###xml 1652 1656 <span type="species:ncbi:10090">mice</span>
The inhibitory effect of TLR4 blockade during systemic LPS challenge depended on both the LPS dose and the 1A6 dose (Fig. S3, A and B, available at ). For example, if 1A6 was applied 4 h after LPS injection, a fully protective 1A6 dose was 30 mg/kg body weight (Fig. S3 C). Mice were completely protected from high-dose LPS shock if 1A6 was applied within a time window of 5 h before challenge and 4 h after challenge (Fig. S3, D and E). The different requirements in respect to 1A6 doses might depend on specific demands for celerity of TLR4 blockade (Fig. S3, B and C). The protective effect of systemic 1A6 administration, however, was not caused by induction of TLR4+ cell-specific depletory activity, and TLR4-MD-2-bound 1A6 persisted on the surface of macrophages in vitro for at least 4 h (Fig. S4, A-C), which indicated a slow TLR4-MD-2-1A6 complex uptake. Based on the results of our KO mice and murine macrophage analyses (Fig. 1), we evaluated dual TLR blockade in respect to its protective potential. To this we applied both mAbs systemically before challenge with antibiotic-treated E. coli. Amounts of serum-borne TNF-alpha, IL-6, and IL-10 were equally low in TLR2-/-/TLR4-/- mice and 1A6/T2.5-treated mice when compared with control mice (Fig. 3, A-C). Notably, upon low-dose S. enterica infection, dual TLR blockade in the absence of antibiotic therapy increased bacterial loads in different compartments 24 h after infection to a significant degree (Fig. 3 D). Failure to apply antibiotic therapy upon acute infection with S. enterica consequently accelerated pathogenesis within the first 12 h, as indicated by increased fatality of mice in which dual TLR blockade was performed (Fig. 3 E).
###end p 14
###begin p 15
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 60 61 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 0 263 0 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Systemic blockade of both TLR4 and TLR2 upon <italic>S</italic>. <italic>enterica</italic> or <italic>E</italic>. <italic>coli</italic> challenge inhibits cytokine release, enhances pathology if an infection is not followed by antibiotic therapy, and protects from septic shock if synchronized with the start of antibiotic therapy.</bold>
###xml 316 317 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 363 364 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 407 408 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 413 414 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 416 420 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 535 538 485 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 531 538 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 543 546 493 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 539 546 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 579 580 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 847 848 797 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 853 854 803 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 856 864 806 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 866 869 816 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ent</italic>
###xml 983 984 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1239 1240 1153 1154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 1245 1246 1159 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1248 1256 1162 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1293 1294 1207 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1383 1384 1297 1298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1389 1396 1303 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1435 1436 1349 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1557 1558 1471 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1563 1564 1477 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1566 1570 1480 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 1576 1577 1490 1491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 1582 1583 1496 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1585 1593 1499 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1636 1637 1550 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1765 1766 1679 1680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 1771 1772 1685 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1774 1778 1688 1692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 1780 1781 1694 1695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1806 1807 1707 1708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1836 1837 1726 1727 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 1842 1843 1732 1733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1845 1853 1735 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1855 1856 1745 1746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 45 56 <span type="species:ncbi:28901">S. enterica</span>
###xml 60 67 <span type="species:ncbi:562">E. coli</span>
###xml 270 274 <span type="species:ncbi:10090">Mice</span>
###xml 413 420 <span type="species:ncbi:562">E. coli</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
###xml 853 864 <span type="species:ncbi:28901">S. enterica</span>
###xml 903 907 <span type="species:ncbi:10090">mice</span>
###xml 1035 1039 <span type="species:ncbi:10090">mice</span>
###xml 1245 1256 <span type="species:ncbi:28901">S. enterica</span>
###xml 1389 1396 <span type="species:ncbi:562">E. coli</span>
###xml 1563 1570 <span type="species:ncbi:562">E. coli</span>
###xml 1582 1593 <span type="species:ncbi:28901">S. enterica</span>
###xml 1771 1778 <span type="species:ncbi:562">E. coli</span>
###xml 1842 1853 <span type="species:ncbi:28901">S. enterica</span>
Systemic blockade of both TLR4 and TLR2 upon S. enterica or E. coli challenge inhibits cytokine release, enhances pathology if an infection is not followed by antibiotic therapy, and protects from septic shock if synchronized with the start of antibiotic therapy. (A-C) Mice received 1A6 and T2.5 mAb (open diamond; n = 6) or isotype control mAb (black triangle; n = 6) 1 h before i.p. challenge with 5 x 107 CFU E. coli that had been pretreated with antibiotics in vitro immediately before injection (blacksquare, square, filled, TLR2-/-/TLR4-/- mice, used as positive control; n = 3). Serum samples drawn as indicated were subjected to ELISA. Each experimental group was analyzed in the course of three individual experiments. (D) Wild-type mice received mAbs (i.c., isotype control; T2.5, anti-TLR2; 1A6, anti-TLR4) 1 h before infection with 106 CFU S. enterica (ent.) by i.p. injection. 24 h later, mice were killed and bacterial loads of compartments indicated were determined (n = 6 for each experimental group). (E-J) Wild-type mice received mAb (open diamond, isotype control; *, 1A6; triangle down, T2.5; black triangle, 1A6 and T2.5; *, P < 0.004 for comparison to specific dual TLR blockade groups): 1 h before infection with 108 CFU S. enterica to be left untreated thereafter (E; n = 7 per group split for three independent experiments), 1 h before infection with 5 x 109 CFU E. coli and 2 h before antibiotic therapy (F; n = 5 per group split for two independent experiments), at the start of antibiotic therapy 1 h after infection with 5 x 109 CFU E. coli or 109 CFU S. enterica (G and H; two individual experiments with n = 5 per group), or (results of three individual experiments) at the start of antibiotic therapy 4 h after infection with 5 x 108 CFU E. coli (n = 9 for black triangle, n = 10 for open diamond) or 108 CFU S. enterica (n = 10 for both experimental groups; I and J).
###end p 15
###begin p 16
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 154 162 154 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 F</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 352 360 352 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 E</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 595 598 595 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 591 598 591 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 672 680 672 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 752 755 752 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 748 755 748 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 823 826 819 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 819 826 815 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 895 896 891 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 116 123 <span type="species:ncbi:562">E. coli</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
###xml 827 831 <span type="species:ncbi:10090">mice</span>
Surprisingly, prophylactic pretreatment with 1A6 alone, but not T2.5 alone, protected WT mice from otherwise lethal E. coli infection/antibiotic therapy (Fig. 3 F and not depicted). Accordingly, early TLR4 blockade in otherwise untreated experimental peritonitis has been protective (16). Our findings on the necessity of concordant dual TLR blockade (Fig. 2 E), however, somehow opposed exclusiveness of TLR4 involvement; possibly caused by the high TLR2 expression level in RAW264.7 macrophages used in our initial experiments here, which is not apparent in primary macrophages (19). That TLR4-/- mice lacked significant resistance to Gram-negative bacterial challenge (Fig. 1 C) could not be explained by a compensatory hyperactivity of TLR2 in TLR4-/- mice, because average serum TNF-alpha concentrations in WT and TLR4-/- mice upon challenge with bacterial lipopeptide analogue for 90 min (n = 14 for each of the two genotypes) did not differ significantly (not depicted). Instead, a systemically operative TLR4-TLR2 interrelation, which is outlined in the following paragraphs, provides a possible explanation for the effectiveness of TLR4 preblockade.
###end p 16
###begin p 17
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 114 122 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 387 402 387 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, G and H</xref>
###xml 522 537 522 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, G and H</xref>
###xml 663 678 663 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, I and J</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 100 107 <span type="species:ncbi:562">E. coli</span>
###xml 111 122 <span type="species:ncbi:28901">S. enterica</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
In modeling treatment of an established Gram-negative bacterial sepsis, we first infected mice with E. coli or S. enterica. After 1 h, an initial antibiotics administration was performed that was accompanied by application of either one of the two mAbs or both mAbs together. In accordance with the results of our initial experiments, neither of the two mAbs alone conferred protection (Fig. 3, G and H). Notably, dual mAb application resulted in complete protection against infection/antibiotics treatment-induced shock (Fig. 3, G and H). Dual TLR blockade was protective, even if performed in synchrony with the start of antibiotic therapy 4 h after infection (Fig. 3, I and J), even though mice already displayed symptoms of severe illness 3 h after infection. The 4-h time window of effective treatment is consistent with specific mAb-mediated protection upon single TLR-specific challenge (Fig. S3 E) (19). Our findings suggest effectiveness of TLR2/TLR4 blockade in the advanced phase of sepsis pathogenesis in which infection becomes clinically manifest, and therefore antibiotics are applied.
###end p 17
###begin p 18
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 412 427 412 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, D and E</xref>
###xml 476 484 476 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 J</xref>
###xml 662 663 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 665 673 665 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 714 715 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 717 721 717 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 770 771 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 773 781 773 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 830 831 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 833 837 833 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 15 22 <span type="species:ncbi:562">E. coli</span>
###xml 95 102 <span type="species:ncbi:562">E. coli</span>
###xml 369 380 <span type="species:ncbi:28901">S. enterica</span>
###xml 662 673 <span type="species:ncbi:28901">S. enterica</span>
###xml 714 721 <span type="species:ncbi:562">E. coli</span>
###xml 770 781 <span type="species:ncbi:28901">S. enterica</span>
###xml 830 837 <span type="species:ncbi:562">E. coli</span>
Infection with E. coli is among the most important causes of sepsis (4), which might depend on E. coli access to the bloodstream by mechanisms such as trauma. In contrast, salmonellae cause enteric disease because of their capacity to traverse epithelial cells lining the intestine or upon breaching tight junctions between them (20). However, only upon infection with S. enterica alone for longer time periods (Fig. 3, D and E), or if antibiotic therapy was delayed for 4 h (Fig. 3 J), might epithelial breakage or intracellular inhabitation have contributed to evasion from host surveillance, and thus to the increase of bacterial load. Indeed, infection with S. enterica was more pathogenic than infection with E. coli as judged from the necessity for application of S. enterica doses that were reduced by 80% as compared with E. coli doses to induce similar hyperinflammation, despite antibiotic therapy.
###end p 18
###begin p 19
###xml 104 119 104 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, F and G</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 410 418 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 659 667 651 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
We speculated that the startling protection by TLR4 blockade before infection, but not after infection (Fig. 3, F and G), might indicate a TLR2 trigger function of TLR4 (21). To evaluate this hypothesis, we challenged mice with TLR2 and TLR4 ligands consecutively, at a low dose. Serum TNF-alpha concentrations peaked at 90 min and were reduced to background levels 180 min after single challenge of each TLR (Fig. 4 A and not depicted). Consistently, sequential (3-h interval) TLR4-TLR2 activation caused the strongest serum TNF-alpha accumulation after 4.5 h, as compared with single TLR2, TLR2-TLR4, TLR2-TLR2, or even single TLR4 or TLR4-TLR4 activation (Fig. 4 A). This finding was paralleled by the persistence of an increased TNF-alpha level 180 min after the second challenge (6 h upon first challenge) and a fatal outcome upon consecutive TLR4-TLR2 challenge specifically (not depicted). Thus, enhanced TLR2 sensitivity rather than tolerance was operative upon TLR4 activation.
###end p 19
###begin p 20
###xml 0 261 0 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Timely graduated TLR4&#8211;TLR2 activation induces maximal cell activation and correlates with TLR4- and MyD88-dependent release of IFN-&#947; by NK and NKT cells to enhance TLR2-specific sensitivity and surface TLR2 expression upon Gram-negative bacterial infection.</bold>
###xml 359 360 353 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 399 400 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 593 594 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 599 606 593 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 612 613 606 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 618 629 612 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. enterica</italic>
###xml 631 635 625 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ent.</italic>
###xml 733 734 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 740 741 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 759 762 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 755 762 749 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 850 851 844 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 856 857 850 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 859 867 853 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 879 880 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 888 889 882 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1064 1067 1048 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1060 1067 1044 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIF<sup>&#8722;/&#8722;</sup></italic>
###xml 1115 1118 1073 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1110 1118 1068 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MyD88<sup>&#8722;/&#8722;</sup></italic>
###xml 1148 1151 1106 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1144 1151 1102 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIF<sup>&#8722;/&#8722;</sup></italic>
###xml 1157 1160 1115 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1157 1160 1115 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink"><sup>&#8722;/&#8722;</sup></italic>
###xml 1497 1498 1433 1434 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1501 1502 1437 1438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1707 1708 1643 1644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1710 1718 1646 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1740 1741 1676 1677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 1785 1786 1721 1722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 266 270 <span type="species:ncbi:10090">Mice</span>
###xml 563 567 <span type="species:ncbi:10090">Mice</span>
###xml 599 606 <span type="species:ncbi:562">E. coli</span>
###xml 618 629 <span type="species:ncbi:28901">S. enterica</span>
###xml 781 787 <span type="species:ncbi:10090">Murine</span>
###xml 856 867 <span type="species:ncbi:28901">S. enterica</span>
###xml 1193 1197 <span type="species:ncbi:10090">mice</span>
###xml 1707 1718 <span type="species:ncbi:28901">S. enterica</span>
###xml 1732 1736 <span type="species:ncbi:10090">mice</span>
Timely graduated TLR4-TLR2 activation induces maximal cell activation and correlates with TLR4- and MyD88-dependent release of IFN-gamma by NK and NKT cells to enhance TLR2-specific sensitivity and surface TLR2 expression upon Gram-negative bacterial infection. (A) Mice were challenged by i.p. injection of 50 mug LPS or 50 mug dipalmitoylated hexapeptide (P2C), or they were left untreated (none; n = 6 per experimental group). After a second challenge (or none) at 180 min, serum was drawn at 270 min and analyzed by ELISA. *, P < 0.004. ND, not detected. (B) Mice were infected with 5 x 108 CFU E. coli or 108 CFU S. enterica (ent.) for 3 h, after which serum was sampled and analyzed by ELISA. *, P < 0.004 (inf., infected; WT, n = 4; n = 3 for each TLR4-/- group). (C and D) Murine splenocytes were prepared 2 h after systemic infection with 108 CFU S. enterica. Viable CD3- and CD3+ fractions of splenocytes were analyzed for NK 1.1 (NK and NKT, respectively) and intracellular IFN-gamma expression. (E) Splenocytes from wild-type (diamond, white bar), TRIF-/- (blacksquare, square, filled, black bar), MyD88-/- (*, light gray bar), and TRIF-/-/MyD88-/- (black triangle, dark gray bar) mice were challenged for 24 h ex vivo upon which supernatants were analyzed by ELISA (3.5 mug/ml alphaCD3 as control, represents two independent experiments). (F) Primary macrophages were IFN-gamma primed for 3 h or left untreated (-). Cells were washed twice and challenged with 1 ng/ml lipopeptide (Pam3CSK4, white bars), 10 ng/ml (gray bars), or 100 ng/ml (black bars) for an additional 6 h and analyzed by ELISA. *, P < 0.006 (represents three independent experiments). (G) Splenocytes were isolated 3 h after S. enterica infection of mice (108 CFU) with indicated genotypes and the CD11b+ fraction was analyzed for surface TLR2 expression (representative of at least three independent experiments).
###end p 20
###begin p 21
###xml 209 211 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 282 290 274 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 F</xref>
###xml 471 479 459 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 503 504 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 509 510 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 527 528 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 533 534 521 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 671 672 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 674 682 658 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 770 773 750 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 766 773 746 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 780 795 760 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, C and D</xref>
###xml 1013 1014 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1130 1138 1102 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 E</xref>
###xml 1240 1248 1208 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 F</xref>
###xml 1311 1312 1279 1280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1343 1344 1311 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1346 1354 1314 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 1432 1435 1400 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1428 1435 1396 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 1472 1475 1432 1435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1462 1475 1426 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFN-&#947;R<sup>&#8722;/&#8722;</sup></italic>
###xml 1483 1491 1443 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 G</xref>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 671 682 <span type="species:ncbi:28901">S. enterica</span>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 1343 1354 <span type="species:ncbi:28901">S. enterica</span>
###xml 1477 1481 <span type="species:ncbi:10090">mice</span>
We reasoned that IFN-gamma might mediate the TLR4-dependent effect described above, because impairment of IFN-gamma function has been reported to attenuate Gram-negative bacterial challenge-induced pathology (22), and because of the protective effect of prophylactic TLR4 blockade (Fig. 3 F). Accordingly, Gram-negative bacterial infection caused accumulation of substantial amounts of IFN-gamma within a 3-h time frame in the sera of WT mice in a TLR4-dependent manner (Fig. 4 B). Splenic NK cells (CD3-NK1.1+), NKT cells (CD3+NK1.1+), and a low but substantial frequency of T cells from WT mice were found to already express IFN-gamma 2 h after systemic infection with S. enterica, whereas the number of IFN-gamma producers was substantially lower in spleens from TLR4-/- mice (Fig. 4, C and D, and Fig. S5, A and B, available at ). Activated TLR4 induces proinflammatory cytokine production by recruitment of MyD88, whereas it mediates late NF-kappaB activation and type I IFN- synthesis through TRIF/TICAM-1 (7). Notably, TLR4-driven IFN-gamma release from splenocytes was MyD88-dependent, but did not depend on TRIF/TICAM-1 (Fig. 4 E). In addition, IFN-gamma priming for 3 h increased cellular responsiveness to TLR2 ligand challenge (Fig. 4 F) and cell surface TLR2 expression on C57BL/6 or 129Sv WT CD11b+ cells was increased 3 h after S. enterica infection, whereas an up-regulation of TLR2 was undetectable in infected TLR4-/- and IFN-gammaR-deficient (IFN-gammaR-/-) mice (Fig. 4 G and not depicted).
###end p 21
###begin p 22
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 553 561 549 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 642 643 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 645 649 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 766 774 754 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 888 896 872 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 114 120 <span type="species:ncbi:9606">humans</span>
###xml 211 219 <span type="species:ncbi:9606">children</span>
###xml 642 649 <span type="species:ncbi:562">E. coli</span>
Our findings are consistent with both TLR2 mRNA augmentation and cell surface TLR2 increase upon LPS challenge in humans (23, 24). They also correspond with the enhanced cell surface TLR2 expression in farmers' children as compared with controls, a finding that has been linked to exposure to higher amounts of LPS (25). The translation potential of our preclinical data is further supported by the effective inhibition of TNF-alpha release from hPBMCs upon infection with each of the two Gram-negative bacteria through mAb-mediated TLR2/TLR4 blockade (Fig. 5 A). TLR4, but not TLR2, blockade on hPBMCs inhibited rapid IFN-gamma release upon E. coli infection. Accordingly, although LPS challenge induced IFN-gamma release from hPBMCs, acylated hexapeptide did not (Fig. 5 B). Furthermore, IFN-gamma challenge enhanced TLR2-specific hPBMC activation if applied 3 h before TLR2 challenge (Fig. 5 C).
###end p 22
###begin p 23
###xml 0 239 0 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dual TLR blockade inhibits TNF-&#945; release, whereas TLR4-specific blockade impedes IFN-&#947; release from hPBMCs upon Gram-negative bacterial infection and IFN-&#947; enhances TLR2-specific, but not TLR4-specific responsiveness of hPBMCs.</bold>
###xml 414 425 373 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. enterica</italic>
###xml 429 436 388 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 675 676 634 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 689 690 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 698 699 657 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 701 705 660 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 902 903 860 861 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 906 907 864 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1323 1324 1273 1274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1327 1328 1277 1278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1362 1363 1312 1313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1371 1372 1321 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1374 1378 1324 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">coli</italic>
###xml 414 425 <span type="species:ncbi:28901">S. enterica</span>
###xml 429 436 <span type="species:ncbi:562">E. coli</span>
###xml 698 705 <span type="species:ncbi:562">E. coli</span>
###xml 1371 1378 <span type="species:ncbi:562">E. coli</span>
Dual TLR blockade inhibits TNF-alpha release, whereas TLR4-specific blockade impedes IFN-gamma release from hPBMCs upon Gram-negative bacterial infection and IFN-gamma enhances TLR2-specific, but not TLR4-specific responsiveness of hPBMCs. (A) hPBMCs were preincubated with mAbs for 30 min (*, 15C1; square, T2.5; black triangle, 15C1 and T2.5; open diamond, isotype control), infected with the indicated doses of S. enterica or E. coli, and treated by application of antibiotics after 1 h. Supernatant was analyzed 6 h after infection by ELISA. Illustration represents one out of three equivalent results of three independent experiments. (B) 30 min before infection with 105 CFU/ml or 106 CFU/ml E. coli and subsequent antibiotic therapy, hPBMCs were pretreated with mAbs (i.c., isotype control). Nonpretreated cells were challenged with 100 ng/ml or 1 mug/ml LPS or tripalmitoylated hexapeptide (Pam3CSK4). Triangles indicate smaller and larger doses. IFN-gamma in the supernatants was analyzed 16 h after challenge by ELISA (ND, not detected; illustration represents summarized results of three independent experiments; *, P = 0.027). (C) hPBMCs were primed with IFN-gamma for 3 h (shaded bars) or left untreated (open bars). Subsequently, cells were washed twice by centrifugation and challenged with TLR agonists (Pam3CSK4, lipopeptide) or infected with 106 CFU/ml E. coli and subjected to antibiotic therapy after 1 h. Supernatants sampled 5 h after challenge were analyzed by ELISA (summarized result of five independent experiments; *, P < 0.02; **, P = 0.26).
###end p 23
###begin p 24
###xml 555 557 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 559 561 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
Antagonism of primary inflammatory mediators, such as of TNF-alpha, IL-6, or IL-1beta, is being evaluated. Blockades of different cytokines are currently being used as therapies of chronic inflammatory diseases. Yet, they have proved less successful for the treatment of acute infection, possibly caused by redundant activities via untargeted cytokines. Targeting late mediators of sepsis has proved successful in experimental models of sepsis, as demonstrated by antagonism of macrophage migration inhibitory factor or high-mobility group box 1 protein (26, 27). Using an experimental model of hyperinflammation induced by Gram-negative bacterial infection coupled to antibiotic therapy, we show a 4-h window of opportunity for protective TLR2/TLR4 blockade, contrasting the hypothesis of immediate early TLR activation as a point of no return. Our data also imply a time-dependent accumulation of inflammatory TLR signals encompassing one signal that "switches on" second line TLR2-specific sensitivity, which might depend on first line TLR4 activation upon a Gram-negative bacterial insult. Therefore, effective interference with pattern recognition concomitant with initiation of antibiotic therapy might be possible even in an advanced phase of sepsis pathology after infection. It is conceivable that dual TLR antagonism (as demonstrated in this study), as well as late mediator blockade and other concepts of sepsis pathology inhibition might have to match with each other or complement one another to define the most effective therapy.
###end p 24
###begin p 25
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 246 254 246 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
It remains to be shown whether, in addition to averting a "storm" of cytokines, transient TLR blockade upon infection also reduces sepsis-related apoptosis and/or immunoparalysis (5), as deduced from TLR2/TLR4 blockade-dependent IL-10 reduction (Fig. 3 C). In conclusion (Fig. S6, available at ), our data implicate IFN-gamma as a TLR4-MyD88-driven inducer of up-regulation of surface TLR2 expression and toxemia-related TLR2 sensitivity. Our preclinical results suggest that blockade of both TLR2 and the TLR4-MD-2 complex is a therapeutic approach to effectively inhibit Gram-negative bacterial infection-induced immunopathology during antibiotic therapy.
###end p 25
###begin title 26
MATERIALS AND METHODS
###end title 26
###begin title 27
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Reagents, bacteria, cells, cell lines, mice, and TLR2/TLR4 blockade.
###end title 27
###begin p 28
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 660 662 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 664 666 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 746 748 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 839 850 826 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. enterica</italic>
###xml 895 902 882 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 9 20 <span type="species:ncbi:28901">S. enterica</span>
###xml 319 324 <span type="species:ncbi:10090">mouse</span>
###xml 466 469 <span type="species:ncbi:10116">rat</span>
###xml 487 492 <span type="species:ncbi:10090">mouse</span>
###xml 566 569 <span type="species:ncbi:10116">rat</span>
###xml 596 601 <span type="species:ncbi:10090">mouse</span>
###xml 619 624 <span type="species:ncbi:10090">mouse</span>
###xml 839 850 <span type="species:ncbi:28901">S. enterica</span>
###xml 895 902 <span type="species:ncbi:562">E. coli</span>
###xml 1522 1526 <span type="species:ncbi:10090">mice</span>
LPS from S. enterica serovar Minnesota strain R595, polyinosinic-polycytidylic acid (poly-I:C; both from Sigma-Aldrich) and di- or tripalmitoyl-cysteinyl-seryl-(lysyl)3-lysine (EMC microcollections) were applied at 100 ng/ml unless otherwise indicated. Thiolated DNA (#1668) was applied at 2 muM (TIB MOLBIOL) and anti-mouse-CD3epsilon was applied at 1 mug/ml (145-2C11; BD Biosciences), or IFN-gamma (PeproTech) at 20 ng/ml. As the isotype-matched control for 1A6 (rat IgG2b) and T2.5 (mouse IgG1, mTLR2, and hTLR2-specific; HBT), equal amounts of unspecific 11G8 (rat IgG2b) and mTLR2-specific mouse mT2.13 (neutral, mouse IgG1), respectively, were blended (12, 19). Anti-hTLR4 mAb (15C1; isotype control mT2.13) has been previously described (12). mAbs were applied at 25 mug/ml in vitro or 30 mg/kg in vivo. Clinical isolate clones of S. enterica subspecies enterica serovar enteritidis and E. coli were cultured (16 h, 37degreesC) in standard media. Bacteria were used for infections both in vivo and in vitro. The bacterial dosage applied in vivo corresponded to a minimal dose that was lethal, despite antibiotic therapy. For antibiotic therapy in vitro, antibiotics (100 mug/ml ampicillin, 10 mug/ml ofloxacin; Sigma-Aldrich) were applied once 1 h after infection. Upon systemic infection, 68 mg/kg ampicillin and 2.8 mg/kg ofloxacin were applied i.p. at the antibiotic therapy starting time points indicated, and an additional 3 times (hourly) without mAbs. For determination of bacterial loads upon infection of mice and subsequent cervical dislocation, aliquots of serial dilutions of blood and organ suspensions were plated.
###end p 28
###begin title 29
Immunization and mAb identification.
###end title 29
###begin p 30
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 421 423 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 5 16 <span type="species:ncbi:10116">Wistar rats</span>
###xml 202 206 <span type="species:ncbi:10116">rats</span>
Male Wistar rats were subcutaneously immunized 3 times within 6 wk with 106 CHO/mTLR4-MD-2 cells suspended in monophosphoryl-lipid A/trehalose dicorynomycolate adjuvant (RIBI; Sigma-Aldrich). Immunized rats were challenged subcutaneously with 10 mug recombinant mTLR4-mMD-2 (mTLR4 ectodomain aa 1-629 fused to mMD-2 aa 19-170 via a peptide linker in RIBI). Lymph node cells were fused with Sp2/0 myeloma cells after 3 d (12). Hybridoma supernatants were screened for binding to mTLR4-MD-2 by flow cytometry.
###end p 30
###begin title 31
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 31
###begin p 32
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 57 64 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 225 228 225 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 233 236 233 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 221 236 221 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup>/TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 253 256 253 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 248 256 248 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MyD88<sup>&#8722;/&#8722;</sup></italic>
###xml 265 268 265 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIF<sup>&#8722;/&#8722;</sup></italic>
###xml 359 362 359 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 368 371 368 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 354 371 354 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MyD88<sup>&#8722;/&#8722;</sup>/TRIF <sup>&#8722;/&#8722;</sup></italic>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 470 473 466 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 460 473 460 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFN-&#947;R<sup>&#8722;/&#8722;</sup></italic>
###xml 505 507 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
TLR2-/- (provided by Amgen, South San Francisco, CA) and TLR4-/- (provided by K. Hoshino and S. Akira, Osaka University, Osaka, Japan) mice were backcrossed toward the C57BL/6 background (WT) nine times and intercrossed (TLR2-/-/TLR4-/-) (27, 28). MyD88-/- and TRIF-/- mice were backcrossed toward the C57BL/6 background (WT) six times and intercrossed (MyD88-/-/TRIF -/-; provided by T. Kawaii, K. Hoshino, and S. Akira, Osaka University, Osaka, Japan) (29). IFN-gammaR-/- mice were on 129Sv background (30). All animal experiments were approved by the Government of Upper Bavaria, Germany.
###end p 32
###begin title 33
Flow cytometry.
###end title 33
###begin p 34
###xml 142 145 <span type="species:ncbi:10116">rat</span>
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
###xml 270 273 <span type="species:ncbi:10116">rat</span>
###xml 281 286 <span type="species:ncbi:10090">mouse</span>
###xml 293 298 <span type="species:ncbi:10090">mouse</span>
###xml 304 307 <span type="species:ncbi:10116">rat</span>
###xml 319 322 <span type="species:ncbi:10116">rat</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
CD3 (FITC), IFN-gamma (APC), CD11b (APC), NK1.1 (PE), CD8 (Alexa405), CD4 (PE; all from BD Bioscience), flag-tag (M2; Sigma-Aldrich), MTS510 (rat anti-mouse TLR4; Abcam), and/or TLR2 (FITC, mT2.7, or T2.5; HBT) for analysis by flow cytometry. For detection of unlabeled rat 1A6 or mouse T2.5, mouse anti-rat Fcgamma or rat anti-mouse Fcgamma mAb coupled with FMAT Blue (Applied Biosystems) or FITC (Jackson ImmunoResearch Laboratories), respectively, were used as secondary mAbs. Intracellular IFN-gamma was analyzed using Cytofix/Cytoperm plus fixation/permeabilization and GolgiPlug solutions for incubation of cultured cells 4 h before staining (BD Biosciences). Primary cells were analyzed on a CyAn ADP LX9 analyzer (Dako) using FlowJo software (Tree Star, Inc.). Transfected CHO and HEK293 cells were analyzed using a FACSCalibur (BD Biosciences).
###end p 34
###begin title 35
Analysis of supernatants and sera by ELISA.
###end title 35
###begin p 36
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
Supernatant or mouse serum cytokine concentrations were determined by species-specific TNF-alpha, IL-6, IL-10, and IFN-gamma ELISA (R&D Systems).
###end p 36
###begin title 37
Immunocytochemistry, immunoprecipitation, and immunoblot analysis.
###end title 37
###begin p 38
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 419 420 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 118 122 <span type="species:ncbi:9925">goat</span>
###xml 128 131 <span type="species:ncbi:10116">rat</span>
###xml 175 181 <span type="species:ncbi:9913">bovine</span>
Immunofluorescence analysis of 2% aldehyde-fixed macrophages was performed after TLR4-specific staining using 1A6 and goat anti-rat-Alexa546 (Invitrogen) in 0.2% saponin/0.5% bovine serum albumin with a laser-scanning microscope using LSM Image software (Carl Zeiss, Inc.). Lysates of 4 x 106 cells of a HEK293 line stably overexpressing flag-tagged mTLR4-MD-2 were immunoprecipitated as described for lysates of 5 x 105 RAW264.7 cells applied to immunoblot analysis (19).
###end p 38
###begin title 39
NF-kappaB-driven reporter gene assay.
###end title 39
###begin p 40
###xml 195 197 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
Cell lysates of HEK293 cells transfected with plasmids for expression of PRRs and reporter proteins and challenged specifically were analyzed for NF-kappaB-dependent firefly luciferase activity (19).
###end p 40
###begin title 41
Statistical analysis.
###end title 41
###begin p 42
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Student's t test for unconnected samples was applied for P value calculations. Mortality was analyzed by the Kaplan-Meier and log-rank methods. Differences were considered significant for P < 0.05. All P values are two tailed.
###end p 42
###begin title 43
Online supplemental material.
###end title 43
###begin p 44
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 527 528 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 530 538 526 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">enterica</italic>
###xml 560 561 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 569 570 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 421 427 <span type="species:ncbi:10090">murine</span>
###xml 527 538 <span type="species:ncbi:28901">S. enterica</span>
###xml 670 675 <span type="species:ncbi:9606">human</span>
Fig. S1 illustrates the capacity of 1A6 to stain overexpressed and endogenous cell surface TLR4-MD-2 specifically. Fig. S2 and Fig. S3 provide evidence for effectiveness, specificity, dose-dependence, and duration of 1A6-mediated TLR4-MD-2 blocking in vitro and in vivo, respectively. Fig. S4 demonstrates absence of CD11b+ cell depletion upon systemic 1A6 administration, as well as persistence of 1A6 on the surface of murine macrophages in vitro. Fig. S5 shows TLR4-dependent IFN-gamma production induced by 2 h of systemic S. enterica infection by both CD4+ and CD8+ T cells (flow cytometry), respectively, as well as infection-induced surface TLR2 up-regulation on human PBMCs. Fig. S6 abstracts procedures and findings. The online version of this article is available at .
###end p 44
###begin title 45
Supplementary Material
###end title 45
###begin title 46
[Supplemental Material Index]
###end title 46
###begin p 47
###xml 343 346 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 339 346 339 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR4<sup>&#8722;/&#8722;</sup></italic>
###xml 353 356 353 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 348 356 348 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MyD88<sup>&#8722;/&#8722;</sup></italic>
###xml 374 377 374 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 362 377 362 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRIF/TICAM-1<sup>&#8722;/&#8722;</sup></italic>
###xml 403 406 403 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 399 406 399 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR2<sup>&#8722;/&#8722;</sup></italic>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
We thank S. Fichte for assistance; T. Miethke for provision of clinical isolates of bacteria and N. Wantia for drawing blood from healthy authors to obtain PBMCs; M. Schiemann, C. Stemberger, and D. H. Busch for help with flow cytometry; F. Schmitz and T. Haas for help with microscopy; S. Akira, K. Hoshino, T. Kawai, and M. Yamamoto for TLR4-/-, MyD88-/-, and TRIF/TICAM-1-/- mice; D. Goeddel for TLR2-/- mice; M. Hammer and R. Lang for help with serum IFN-gamma detection; HBT for support with T2.5; and T. Calandra, R. Ulevitch, C. Galanos, U. Koedel, S. Bauer, and G. Hacker for helpful discussions.
###end p 47
###begin p 48
We thank The German Research Foundation for support of this study through SFB/TR22-A5.
###end p 48
###begin p 49
###xml 105 110 <span type="species:ncbi:9606">human</span>
G. Elson and B. Daubeuf are employed by NovImmune SA, Geneva, Switzerland, whose potential product, anti-human TLR4 (15C1) mAb was studied in this work. All other authors declare no financial interests.
###end p 49

